General information
Wacker Biotech GmbH
Hans-Knöll-Str. 3
07745 Jena, Thuringia
Germany
Company main phone: +49 (3641) 53480
Website: https://www.wacker.com/biologics
Year founded: | 1999
|
Source of foundation: | Spin-off from university |
Name of foundation source: | Hans Knöll Institute |
No. of employees: |
At this location: 160 |
Corporate description / mission:
Wacker Biotech GmbH is a contract manufacturer of therapeutic proteins (biologics), vaccines and live microbial products.
Wacker Biotech’s services cover cell banking, process & analytical development and the GMP manufacturing of biologics for clinical & commercial supply.
State of ownership: Subsidiary
Headquarters: No
Categorization
Sector: |
- Biotechnology - R&D Services
|
Subsector: |
- CMO (Contract Manufacturing Organization)
- Fill & finish
|
Business model: |
- Manufacturer
- Service company
- Subsidiary
|
Customer segments: |
- Other
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Description of products:
Recombinant proteins (contract manufacturing)
Technology used:
ESETEC® secretion technology
FOLDTEC® technology
LIBATEC® platform
Collaborations & Clients
Partnering strategy / collaborations:
Wacker Biotech and XL-protein have signed a long-term cooperation agreement to produce PASylated biopharmaceuticals. Through this collaboration, WACKER and its customers gain access to XL-protein's PASylation® platform. The PASylation® technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly. Recently, record yields of 4.3 g/L were obtained for PASylated Fabs using Wacker's ESETEC E. coli secretion technology.